MT-026 / Suzhou Maximum Bio-tech - LARVOL DELTA

Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial. (PubMed, Nat Commun) - P=N/A | "No grade ≥3 adverse events were observed; the predominant treatment-related toxicities were grade 1-2 pyrexia, hypoxia, and vomiting. Trial enrolment was halted after enrolment of the first five patients, however these preliminary clinical data support the potential benefit of locally administered allogeneic universal CAR-T cell therapy for recurrent glioblastoma."

Journal • P1 data • Preclinical • Brain Cancer • Glioblastoma • Glioma • Graft versus Host Disease • High Grade Glioma • Immunology • Oncology • Solid Tumor

T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors (PRNewswire) - "...In addition to MT027, T-MAXIMUM is advancing two other allogeneic CAR-T cell therapy candidates: MT026 and MT020. MT026 targets IL13Rα2 and is being developed for the treatment of solid tumors....MT020 is being developed to treat B-cell related autoimmune diseases."

Pipeline update • Immunology • Solid Tumor

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma (clinicaltrials.gov) - P=N/A | N=12 | Recruiting | Sponsor: Second Affiliated Hospital of Soochow University

CAR T-Cell Therapy • Metastases • New trial • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD276 • PD-L1